title: The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome.
abstract: Recent studies indicate that antidepressant drugs with potent serotonin reuptake inhibiting properties are effective in reducing the symptoms of premenstrual syndrome (PMS). In order to elucidate whether all antidepressant drugs are equally effective in the treatment of PMS or whether potent serotonin reuptake inhibition is a prerequisite for reducing premenstrual complaints, women suffering from severe PMS were treated daily for three menstrual cycles with a selective serotonin reuptake inhibitor, paroxetine (n = 22), or with a selective noradrenaline reuptake inhibitor, maprotiline (n = 21); in addition, a placebo group was included (n = 22). Six symptoms (irritability, depressed mood, tension/anxiety, increased appetite/craving for carbohydrates, bloating, and breast tenderness) were rated by the participants daily throughout the study. With respect to all outcome measurements, the symptom reduction obtained with paroxetine was significantly superior to that obtained with placebo; with respect to irritability, increased appetite/carbohydrate craving, bloating, and breast tenderness, as well as global self-rating, paroxetine was significantly superior also to maprotiline. The clear-cut superiority of paroxetine over maprotiline indicates that not all antidepressant drugs are equally effective in the treatment of PMS; rather, like panic disorder and obsessive compulsive disorder, but in contrast to depression, PMS apparently responds better to serotonin reuptake inhibitors than to antidepressants with a noradrenergic profile.
authors.affiliation: Department of Pharmacology, University of Göteborg, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Eriksson
authors.forename: M A
authors.initials: MA
authors.lastname: Hedberg
authors.forename: B
authors.initials: B
authors.lastname: Andersch
authors.forename: C
authors.initials: C
authors.lastname: Sundblad
mesh_terms: D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008376:Maprotiline / Q000009:adverse effects / Q000627:therapeutic use*; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011293:Premenstrual Syndrome / Q000188:drug therapy* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D008376:Maprotiline; D017374:Paroxetine